Recro Pharma, Inc. (REPH) Given Average Rating of “Buy” by Analysts
Recro Pharma, Inc. (NASDAQ:REPH) has been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.75.
A number of equities research analysts have commented on REPH shares. Piper Jaffray Companies set a $11.00 price objective on Recro Pharma and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Roth Capital set a $20.00 price objective on Recro Pharma and gave the stock a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research report on Wednesday, August 16th. Finally, Janney Montgomery Scott lowered Recro Pharma from a “buy” rating to a “fair value” rating and decreased their price objective for the stock from $21.00 to $6.50 in a research report on Wednesday, June 14th.
Recro Pharma (NASDAQ:REPH) traded up 1.52% on Friday, hitting $7.99. 135,269 shares of the stock were exchanged. Recro Pharma has a 52 week low of $5.81 and a 52 week high of $10.17. The company’s market cap is $152.28 million. The company’s 50-day moving average is $7.45 and its 200-day moving average is $7.60.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.06. Recro Pharma had a negative return on equity of 56.04% and a negative net margin of 46.75%. The business had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.90 million. On average, analysts predict that Recro Pharma will post ($2.35) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Janney Montgomery Scott LLC boosted its position in Recro Pharma by 17.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 12,485 shares of the specialty pharmaceutical company’s stock worth $109,000 after acquiring an additional 1,885 shares during the period. Acadian Asset Management LLC acquired a new stake in Recro Pharma during the 1st quarter worth about $150,000. Wells Fargo & Company MN boosted its position in Recro Pharma by 3.0% during the 1st quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after acquiring an additional 500 shares during the period. Bank of New York Mellon Corp acquired a new stake in Recro Pharma during the 1st quarter worth about $156,000. Finally, KCG Holdings Inc. acquired a new stake in Recro Pharma during the 1st quarter worth about $173,000. Hedge funds and other institutional investors own 65.06% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.